Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease

NCT03285178 is registered in ClinicalTrials.gov with Cyclerion Therapeutics as lead sponsor.

NCT NCT03285178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03285178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease
Lead sponsor
Cyclerion Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2017
Completion date
July 22, 2020
Enrollment
88 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease